Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RITUXIMAB-ABBS vs RIVASTIGMINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RITUXIMAB-ABBS vs RIVASTIGMINE: Safety Overview

Metric RITUXIMAB-ABBS RIVASTIGMINE
Total FAERS Reports 4,347 9,123
Deaths Reported 432 2,232
Death Rate 9.9% 24.5%
Hospitalizations 1,087 2,716
Average Patient Age 53.5 yrs 80.0 yrs
% Female Patients 74.2% 59.5%
FDA Approval Date N/A Apr 21, 2000
Manufacturer N/A Novartis Pharmaceuticals Corporation
Route N/A TRANSDERMAL
Marketing Status Prescription Discontinued